Core Viewpoint - Saint Noble Pharmaceuticals (2257.HK) plans to issue 17.35 million new shares to four investors, including Shanghai-listed Huaxi Biotechnology, at a price of HKD 12 per share, representing a discount of 19.84% from the last closing price of HKD 14.97. The fundraising aims to raise approximately HKD 208 million, with a net amount of about HKD 206 million, to be used for general working capital [1] Group 1 - The share issuance represents approximately 14.16% of the enlarged share capital [1] - The company believes that the subscription will benefit its long-term development and provide an opportunity to raise additional funds [1] - The funds raised will strengthen the company's financial position and expand its shareholder and capital base, promoting future business growth and development [1] Group 2 - The transaction is expected to enhance the liquidity of the company's shares [1]
圣诺医药折让19.84%配股筹逾2亿港元